在新加坡，未经治疗的 CRF01_AE 和 CRF51_01B 感染的 HIV-1 患者中，CXCR4 的使用频率很高。

High prevalence of CXCR4 usage among treatment-naive CRF01_AE and CRF51_01B-infected HIV-1 subjects in Singapore.

机构信息

Institute of Infectious Disease and Epidemiology, Communicable Disease Centre, Tan Tock Seng Hospital, Singapore 308433, Singapore.

出版信息

BMC Infect Dis. 2013 Feb 19;13:90. doi: 10.1186/1471-2334-13-90.

DOI:10.1186/1471-2334-13-90

PMID:23421710

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3585921/

Abstract

BACKGROUND

Recent studies suggest HIV-1 inter-subtype differences in co-receptor usage. We examined the correlation between HIV-1 subtype and co-receptor usage among treatment-naïve HIV-1 subjects in Singapore. Additionally, we investigated whether the subtype co-receptor association was influenced by stage of infection.

METHODS

V3 sequences of HIV-1 envelope protein gp120 were obtained from 110 HIV treatment-naïve patients and genotypic co-receptor tropism determination was performed using Geno2pheno. Two false-positive rate (FPR) cut-offs, 10% and 5.75% were selected for tropism testing.

RESULTS

Subtype assignment of viral strains from 110 HIV-infected individuals based on partial sequencing of HIV-1 pol, gp120 and gp41 were as follows: 27 subtype B, 64 CRF01_AE, 10 CRF51_01B, and 9 other subtypes. At FPR=10%, 10 (100%) CRF51_01B-infected subjects and 26 (40.6%) CRF01_AE-infected subjects had CXCR4-using virus, compared to 7 (25.9%) subtype B subjects and 1 (11.1%) CRF33_01B-infected subject (P < 0.001). At FPR=5.75%, 10 (100%) CRF51_01B-infected subjects and 20 (31.3%) CRF01_AE-infected subjects had CXCR4-using virus, compared to 4 (14.8%) subtype B and 1 (11.1%) CRF33_01B-infected subjects (P < 0.001). Among those with evidence of seroconversion within 2 years prior to study enrolment, 100% of CRF51_01B-infected subjects had CXCR4-using virus, independent of Geno2pheno FPR.

CONCLUSION

CRF51_01B and CRF01_AE-infected individuals have higher prevalence of CXCR4-usage compared to subtype B infected individuals. Further studies examining these differences could help optimise the use of CCR5-antagonist in populations with these subtypes, and increase our understanding of HIV-1 biology.

摘要

背景

最近的研究表明，HIV-1 亚型之间存在共受体使用的差异。我们研究了新加坡未经治疗的 HIV-1 患者中 HIV-1 亚型与共受体使用之间的相关性。此外，我们还研究了感染阶段是否会影响亚型共受体的相关性。

方法

从 110 名未经治疗的 HIV 患者中获得 HIV-1 包膜蛋白 gp120 的 V3 序列，并使用 Geno2pheno 进行基因型共受体嗜性测定。选择了两个假阳性率（FPR）截断值，即 10%和 5.75%，用于嗜性检测。

结果

基于 HIV-1 pol、gp120 和 gp41 的部分测序，对 110 名 HIV 感染者的病毒株进行了亚型分配：27 株为亚型 B，64 株为 CRF01_AE，10 株为 CRF51_01B，9 株为其他亚型。在 FPR=10%时，10（100%）株 CRF51_01B 感染的患者和 26（40.6%）株 CRF01_AE 感染的患者有 CXCR4 使用的病毒，而 7（25.9%）株亚型 B 患者和 1（11.1%）株 CRF33_01B 感染的患者没有（P < 0.001）。在 FPR=5.75%时，10（100%）株 CRF51_01B 感染的患者和 20（31.3%）株 CRF01_AE 感染的患者有 CXCR4 使用的病毒，而 4（14.8%）株亚型 B 患者和 1（11.1%）株 CRF33_01B 感染的患者没有（P < 0.001）。在研究入组前 2 年内有血清转换证据的患者中，100%的 CRF51_01B 感染患者有 CXCR4 使用的病毒，与 Geno2pheno 的 FPR 无关。